首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Gynecologic Oncology

Gynecologic Oncology杂志,由Academic Press Inc.出版,于1972年创刊,Monthly,出版语言English,ISSN:0090-8258,E-ISSN:1095-6859。

投稿咨询
Gynecologic Oncology
Gynecologic Oncology
Gynecologic Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
4.5
CiteScore
7.3
期刊收录
SCI、SCIE

Gynecologic Oncology(中文译名:《妇科肿瘤学》),ISSN:0090-8258,EISSN:1095-6859,是Academic Press Inc.出版的国际性学术期刊,创刊于1972年,以Monthly形式稳定发行,2026年总发文量约281篇。该刊采用非OA开放访问,学科归属为医学 - 妇产科学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.5,2025年期刊CiteScore为7.3,2025年期刊自引率约6.7%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Gynecologic Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约2月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACanada、CHINA MAINLAND、South Korea、Japan、Italy、England等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMMEMORIAL SLOAN KETTERING CANCER CENTER、HARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF ALABAMA SYSTEM、COLUMBIA UNIVERSITY、CORNELL UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 OBSTETRICS & GYNECOLOGY 妇产科学
3区 2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
OBSTETRICS & GYNECOLOGY 妇产科学 ONCOLOGY 肿瘤学
1区 2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
OBSTETRICS & GYNECOLOGY 妇产科学 ONCOLOGY 肿瘤学
1区 2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:OBSTETRICS & GYNECOLOGY SCIE Q1 13 / 143

91.3

学科:ONCOLOGY SCIE Q2 104 / 333

68.9

学科:OBSTETRICS & GYNECOLOGY SCIE Q1 17 / 143

88.46

学科:ONCOLOGY SCIE Q1 57 / 333

83.03

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:OBSTETRICS & GYNECOLOGY SCIE Q1 11 / 141

92.6

学科:ONCOLOGY SCIE Q2 91 / 328

72.4

学科:OBSTETRICS & GYNECOLOGY SCIE Q1 13 / 141

91.13

学科:ONCOLOGY SCIE Q1 50 / 328

84.91


中国学者近期发文

1
CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohort

Author:Wang, Xiuzhen; Zheng, Lang; Zhu, Genhai; Wang, Shengtan; Li, Wei; Liu, Jun; Gao, Haocheng; Liu, Xiaohang; Li, Guifei; Li, Lei; Hong, Lan

Journal: GYNECOLOGIC ONCOLOGY. 2026; Vol. 206, Issue , pp. 82-92. DOI: 10.1016/j.ygyno.2026.01.776

2
Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cance

Author:Tang, Wenjie; Wang, Lu; Li, Xiaolin; Yan, Xiaohui; Guo, Qiufen; Wu, Qian; Cui, Chunhui; Liu, Bowen; Zhang, Jianbo; Zhang, Lu; Zhang, Xueliang; Li, Dapeng; Xie, Peng

Journal: GYNECOLOGIC ONCOLOGY. 2026; Vol. 205, Issue , pp. 17-26. DOI: 10.1016/j.ygyno.2025.12.007

3
Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort stud

Author:Wang, Min; Dong, Tong; Lucero, Maria; Pan, Wanchun; Wang, Xin; Zhou, Ling; Meng, Yuanguang

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 199, Issue , pp. 57-63. DOI: 10.1016/j.ygyno.2025.06.012

4
GTN misdiagnosed as ectopic pregnancy: a 17-year retrospective cohort stud

Author:Liu, Yuanyuan; Zhou, Yusen; Zhou, Ziying; Rao, Xuan; Feng, Liang; Lu, Weiguo; Li, Xiao

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 199, Issue , pp. 27-31. DOI: 10.1016/j.ygyno.2025.06.010

5
Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage III

Author:Gu, Junjie; Zheng, Wang; Li, Fei; Luo, Chengyan; Yuan, Lin; Sasaki, Ryohei; Seno, Satoshi; Tang, Xinyu; Zhang, Qu; Sun, Xinchen; Qin, Qin

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 198, Issue , pp. 17-24. DOI: 10.1016/j.ygyno.2025.05.007

6
Evaluation of mutations detected in uterine exfoliated cells as a diagnostic tool for endometrial cance

Author:Yang, Wenqing; Shen, Yufei; Tian, Yan; Xiao, Xiao; Shao, Zhuo; Xia, Xuefeng; Li, Lucia; Yang, Siyu; Wen, Xinxin; Liu, Yingzhen; Qiu, Minghui; Li, Yi; Yi, Xin; Liu, Qian; Bai, Jing; Wu, Lisha; Zhang, Yu

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 198, Issue , pp. 33-41. DOI: 10.1016/j.ygyno.2025.05.009

7
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cance

Author:Lee, Jung-Yun; Boonyapipatb, Sathana; Yuan, Guangwen; Kim, Hee Seung; Lee, Jeong-Won; Wang, Li; Wang, Tao; Wang, Danbo; Yao, Desheng; Liu, Hu; Chang, Chih-Long; Andabekov, Timur Turdeevich; Zhang, Xiang; Wang, Wei; Kim, Yong Man; Sinielnikov, Ivan Volodymyrovych; Wang, Kai; Gao, Yujuan; Mu, Xiyan; Wu, Lingying

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 198, Issue , pp. 25-32. DOI: 10.1016/j.ygyno.2025.04.579

8
Cognitive outcomes after premenopausal risk-reducing Salpingo-oophorectomy: The role of hormone therap

Author:Zhao, Mei; Xu, Lianwei

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 197, Issue , pp. 179-180. DOI: 10.1016/j.ygyno.2025.03.014

9
FRα expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlate

Author:Xiao, Yinbo; Pang, Junyi; Zhou, Yang; Lu, Junliang; Chen, Longyun; Liu, Hangqi; Shi, Jing; Shi, Xiaohua; Liang, Zhiyong

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 197, Issue , pp. 146-154. DOI: 10.1016/j.ygyno.2025.05.001

10
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 tria

Author:You, Benoit; Anderson, Charles; Cecere, Sabrina Chiara; Carrot, Aurore; Myers, Tashanna; Heitz, Florian; Sharma, Sudarshan; Selcukbiricik, Fatih; Aghajanian, Carol; Fernebro, Josefin; Blank, Stephanie; Laudani, Maria Elena; Thaker, Premal H.; Yunokawa, Mayu; Willmott, Lyndsay; Lisyanskaya, Alla; Hegg, Roberto; He, Yvette; Landen, Charles; Lin, Yvonne G.; Alarcon, Jesus; Moore, Kathleen N

Journal: GYNECOLOGIC ONCOLOGY. 2025; Vol. 197, Issue , pp. 66-73. DOI: 10.1016/j.ygyno.2025.04.577


在线咨询

Gynecologic Oncology

国际简称:GYNECOL ONCOL参考译名:妇科肿瘤学

年发文量:281 CiteScore:7.3 是否预警:否 Gold OA文章占比:21.01% 研究类文章占比:96.80%

杂志社联系方式:ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, USA, CA, 92101-4495

Gynecologic Oncology